Results 31 to 40 of about 2,712 (224)

Analyzing the Therapeutic Efficacy of Bis-Choline-Tetrathiomolybdate in the Atp7b^−/− Copper Overload Mouse Model

Biomedicines, 2021
Bis-choline-tetrathiomolybdate, introduced as WTX101 (now known as ALXN1840), is a first-in-class copper-protein-binding agent for oral therapy of Wilson’s disease.
Philipp Kim, Chengcheng Christine Zhang, Sven Thoröe-Boveleth, Eva Miriam Buhl, Sabine Weiskirchen, Wolfgang Stremmel, Uta Merle, Ralf Weiskirchen   +7 more
doaj   +1 more source

Management of children and adolescents with Wilson Disease and neurological worsening following D–Penicillamine therapy: A single centre experience

Annals of Indian Academy of Neurology, 2022
Background: Most centers in developing countries prefer chelation therapy with D-penicillamine for the management of Wilson's disease (WD) because of its easy availability and affordability. Neurological worsening following treatment with D-penicillamine
Madhan Kumar, T P Murugan, Arul P Lionel, Maya M Thomas, Pavithra Mannam, Sangeetha Yoganathan   +5 more
doaj   +1 more source

Trientine ameliorates bleomycin-induced pulmonary fibrosis in rats through copper chelation and modulation of the CTR1/LOX/COL pathway. [PDF]

Inflammopharmacology
Pulmonary fibrosis (PF) remains a devastating disease. Copper (Cu), an essential trace element, has been implicated in fibrotic processes in various organs, including the lungs. This study investigated the potential protective effects of trientine (TRI),
Khalil IT, Elshal M, Elsayed NM, Radwan A.   +3 more
europepmc   +2 more sources

Catatonia: A rare presentation of Wilson's disease

Industrial Psychiatry Journal, 2021
Wilson's disease (WD) or hepatolenticular degeneration is a rare inherited disorder of copper metabolism affecting both the liver and the central nervous system.
Supriya Davis, Jwalant Chag, Salesh Rohatgi, Suprakash Chaudhury, Daniel Saldanha   +4 more
doaj   +1 more source

Trientine tetrahydrochloride (Cuprior) [PDF]

, 2019
Use of trientine tetrahydrochloride for the treatment of Wilson's disease.
Purchase, Rupert
openaire   +2 more sources

Trientine Hydrochloride (MAR-Trientine)

Canadian Journal of Health Technologies, 2021
CADTH recommends that MAR-Trientine should be reimbursed by public drug plans for the treatment of patients with Wilson's disease if certain conditions are met. MAR-Trientine should only be covered to treat patients who have previously tried and demonstrated intolerance to d-penicillamine. MAR-Trientine should only be reimbursed if ...
openaire   +3 more sources

Trientine Hydrochloride (Waymade-Trientine)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +2 more sources

Costly choices for treating Wilson's disease [PDF]

, 2015
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110871/1/hep27663 ...
Askari, Frederick, Hahn, Sihoun, Roberts, Eve A., Schilsky, Michael L.   +3 more
core   +1 more source

Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans

Hepatology, 2023
Background and Aims: Trientine (TRI) and D-penicillamine (PEN) are used to treat copper overload in Wilson disease. Their main mode of action is thought to be through the facilitation of urinary copper excretion. In a recent study, TRI was noninferior to
F. Kirk, Ditte Emilie Munk, Eugene Scott Swenson, Adam M. Quicquaro, M. Vendelbo, Michael L. Schilsky, Peter Ott, T. Sandahl   +7 more
semanticscholar   +1 more source

Bioavailable Trace Metals in Neurological Diseases [PDF]

, 2016
Medical treatment in Wilson’s disease includes chelators (d-penicillamine and trientine) or zinc salts that have to be maintain all the lifelong. This pharmacological treatment is categorised into two phases; the first being a de-coppering phase and the ...
A Ahuja, A Czlonkowska, A Donsante, A Groger, A Ignjatovic, AC Crespo, AD Monnot, AJ Coffey, Aurélia Poujois, B Yao, BE Needham, BS Choi, BX Wong, BX Wong, C Camaschella, C Guo, C Langkammer, C Quintana, C Veyrat-Durebex, CA Shaw, Caroline Moreau, D Berg, D Devos, D Martinelli, David Devos, DT Dexter, E Brodkin, E Milusheva, EJ Martinez-Finley, F Woimant, France Woimant, G Abbruzzese, G Cairo, G Cossu, G Du, G Zorzi, G Zorzi, GJ Brewer, H Xu, H Zischka, I Bremner, J Lhermitte, J Lotharius, JA Duce, James A. Duce, Jean-Christophe Devedjian, JL Roybal, JM Trocello, JM Trocello, JN Guzman, JR Connor, JR Prohaska, JS Kauwe, JT Rogers, JY Kwan, K Ikeda, KH Weiss, KH Weiss, KJ Klos, L Wan, L Wan, L Zecca, LI Wallis, MM Zeineh, N Krebs, O Bandmann, O Guillaud, O Kakhlon, P Delangle, P Huppke, P Lei, P Peran, Pascal Chaine, PK Sethi, Q Wang, R Chamberlain, RC McCarthy, RE Fleming, S Ayton, S Ayton, S Balkhi El, S Levi, S Lutsenko, S Przedborski, SG Kaler, SG Kaler, SY Jeong, T Ducic, T Haraguchi, T Moos, T Teodoro, TA Rouault, TA Rouault, TR Guilarte, TR Halfdanarson, TW Clarkson, U Merle, V Medici, XW Su, Y Nadjar, YS Sohn, ZI Cabantchik   +101 more
core   +1 more source